Latest news with #PSMA-PET
Business Wire
22-05-2025
- Business
- Business Wire
CORRECTING and REPLACING Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)." Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer. Share The updated release reads: FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025 Flatiron's 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research. Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care. 'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.' Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li Genitourinary—Prostate, Testicular, and Penile Poster board: 295 Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal Quality Care/Health Services Research Poster board: 436 Abstract number: 11097 Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster board: 199 Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster board: 486b Abstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals Online publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia Online publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu Online publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh Online publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter Online publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee Online publication only Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Online publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour Online publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Business Wire
22-05-2025
- Business
- Business Wire
Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care. Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer. Share 'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.' Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Partners: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. Cohen Breast Cancer—Local/Regional/Adjuvant Poster board: 148 Abstract number: 555 Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li Genitourinary—Prostate, Testicular, and Penile Poster board: 295 Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal Quality Care/Health Services Research Poster board: 436 Abstract number: 11097 Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster board: 199 Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster board: 486b Abstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals Online publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia Online publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu Online publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh Online publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter Online publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee Online publication only Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Online publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour Online publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Yahoo
19-05-2025
- Business
- Yahoo
Telix at ANZSNM Annual Scientific Meeting 2025
MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in Melbourne, Australia from 23–25 May 2025. Telix will feature prominently in the scientific program with eight oral and three poster presentations highlighting the Company's late-stage and next-generation programs. Demonstrating its commitment to development and education in theranostics, Telix presentations include: ProstACT Global Phase 3 study of TLX591 (177Lu-rosopatamab tetraxetan)[1], Telix's first-in-class PSMA[2] targeting radio antibody-drug conjugate (rADC) therapy candidate STARSTRUCK study of TLX250 (177Lu-girentuximab) in combination with peposertib[3] in patients with carbonic anhydrase IX (CAIX)-expressing solid tumors[4], and a preclinical evaluation of 225Ac-girentuximab in combination with DNA damage response inhibition Zolar study of TLX300-CDx (89Zr-olaratumab)[5], a theranostic approach in soft tissue sarcoma ZIRCON-CP study of TLX250-CDx (Zircaix®[6], 89Zr-girentuximab), Telix's kidney cancer PET[7] radiodiagnostic candidate in Chinese patients with indeterminate renal masses[8] TLX250-CDx early access in Australia and Italy highlighting clinical utility in clear cell renal cell carcinoma (ccRCC) D2, a first-in-class, dual-chelator theranostic that could enable the use of imaging-therapy radiometal pairs of different elements[9] Artificial intelligence (AI) enabled PSMA-PET/CT[10] lesion delineation for prostate cancer. Telix will also host a Breakfast Symposium showcasing real-world experience and impact on clinical decision making with TLX250-CDx, and clinical utility of PSMA-PET. Again we are pleased to support the Nurses' Workshop in collaboration with with the Prostate Cancer Foundation of Australia (PCFA), NeuroEndocrine Cancer Australia (NECA) and the Peter MacCallum Cancer Centre in Melbourne. Telix will be at booth #28, where visitors can learn more about Telix's extensive late-stage theranostic pipeline in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, our associated medical technologies and AI innovations, and opportunities for collaboration. Details of ANZSNM ASM 2025 abstract presentations related to Telix programs are listed below and the full congress program can be accessed here. All times AEST. Saturday, 24 May 2025 Title: Preclinical evaluation of DNA damage response inhibitors and 225Ac-DOTA-girentuximab combination therapyPresenter: Zhipeng Cao, Olivia Newton-John Cancer Research InstituteTime: 11:00 AM – 12:30 PMSession: RPS Session including Shimadzu AwardLocation: Meeting Room 204 Title: D2 – Enabling a theranostic approach with 89Zr/177Lu in a single trifunctional ligand scaffoldPresenter: James Wood, The University of QueenslandTime: 11:00 AM – 12:30 PMLocation: Meeting Room 204Session: RPS Session including Shimadzu Award Sunday, 25 May 2025 Title: A preliminary study on nnUNet-based PSMA-PET/CT lesion segmentation models: toward clinically informed trainingPresenter: David Han, Telix PharmaceuticalsTime: 11:00 AM – 12:30 PMLocation: Meeting Room 204Session: Scientific Session: Oncology 3 Title: ZOLAR, an open-label, Phase 1 study to assess safety, tolerability, dosimetry, pharmacokinetics, and imaging properties of 89Zr-olaratumab (TLX300-CDx) in patients with soft tissue sarcomaPresenter: Corinne Letendre, Telix PharmaceuticalsTime: 11:00 AM – 12:30 PMLocation: Meeting Room 203Session: Scientific Session: Therapy / Phase 1 Trials Title: ProstACT Global, a multinational, multicenter, prospective, randomized, controlled, open-label, Phase 3 study of 177Lu -rosopatamab tetraxetan (TLX591) in combination with standard of care (SoC) versus SoC alone in patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibitor (ARPI) treatmentPresenter: Veronica Wong, Nepean HospitalTime: 11:00 AM – 12:30 PMLocation: Meeting Room 203Session: Scientific Session: Therapy / Phase 1 Trials Title: STARSTRUCK, a Phase 1b dose escalation/expansion study of the combination of 177Lu-girentuximab (TLX250) and peposertib in patients with carbonic anhydrase IX (CAIX)-expressing solid tumorsPresenter: Aviral Singh, GenesisCareTime: 11:00 AM – 12:30 PMLocation: Meeting Room 203Session: Scientific Session: Therapy / Phase 1 Trials Title: ZIRCON-CP, a confirmatory, open-label, single-arm, multicenter study to evaluate the safety, tolerability, and diagnostic performance of 89Zr-girentuximab (TLX250-CDx) to non-invasively detect ccRCC by PET/CT imaging in Chinese patients with indeterminate renal massesPresenter: Mary Jessel, Telix PharmaceuticalsTime: 2:00 PM - 3:30 PMLocation: Meeting Room 207Session: Scientific Session: Oncology Preclinical Title: Preliminary investigation of radiation exposure of pathology staff from urine samples containing traces of 177Lu-rosopatamab tetraxetan (TLX591)Presenter: Alessandra Malaroda, Nepean HospitalTime: 2:00 PM - 3:30 PMLocation: Meeting Room 204Session: Scientific Session: Oncology 4 Posters: Displayed throughout meeting Title: Non-invasive detection of Nectin-4 and TROP2 in bladder cancer via ImmunoPETPresenter: Peter Chandler, Telix Pharmaceuticals Title: Initial experience with 89Zr-girentuximab (TLX250-CDx)Presenter: Alexis Dalagiorgos, Jones Radiology Title: The emerging role of 89Zr-girentuximab (TLX250-CDx) PET/CT in the management of ccRCC: Early experience in three patientsPresenter: Fabrizia Gelardi, Università Vita-Salute San Raffaele, Milan (Italy) Breakfast Session and Nurses Workshop Telix-Hosted BreakfastLocation: Meeting Room 203Date and Time: Sunday, 25 May | 7:15 AM – 8:15 AMTopics and Presenters: Enhancing cancer care with precision radiopharmaceuticals: Expanded access for renal cancers – Sze Ting Lee, Austin Health Early diagnosis with PSMA-PET in prostate cancer – Michael Kitchener, Jones Radiology Nurses WorkshopLocation: Meeting Room 205Date and Time: Saturday, 24 May | 12:30 PM – 1:30 PMTopics and Presenters: Interpreting liver function tests – Emma Boehm, Peter MacCallum Cancer Centre Gallium-68 PET, FDG PET and other imaging modalities – Aaron Wong, Peter MacCallum Cancer Centre Managing toxicities in theranostics – Gabby Cehic AM, SA Health Radiation safety during radiopharmaceutical therapy – Daniel Badger, SA Health About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, has been approved by the United States Food and Drug Administration (FDA)[11], by the Australian Therapeutic Goods Administration (TGA)[12], by Health Canada[13], by the Brazilian Health Regulatory Agency (ANVISA)[14], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[15], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[16] and in multiple countries within the European Economic Area (EEA)[17] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[18]. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[19]. TLX591, TLX250, TLX250-CDx and TLX300-CDx have not received a marketing authorization in any jurisdiction and are for investigational use only. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] ID: NCT06520345 [2] Prostate-specific membrane antigen. [3] A Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate (M3814). [4] ID: NCT05868174 [5] ID: NCT06537596 [6] Brand name subject to final regulatory approval. [7] Positron emission tomography. [8] ID: NCT06750419 [9] Wood et al. Chem. Sci., 2024. [10] Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography. [11] Telix ASX disclosure 20 December 2021. [12] Telix ASX disclosure 2 November 2021 [13] Telix ASX disclosure 14 October 2022. [14] Telix ASX disclosure 18 March 2025. [15] Telix ASX disclosure 13 February 2025. [16] Telix media release 29 April 2025. [17] Czech Republic, Denmark, Finland, Ireland, Luxembourg, Malta, the Netherlands, Norway and Sweden at time of release. [18] Telix ASX disclosure 17 January 2025. [19] Telix ASX disclosure 21 March 2025. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Health
- Yahoo
Weill Cornell receives grant to test new imaging approach for prostate cancer
Weill Cornell Medicine in the US has secured a grant of approximately $4m from the National Cancer Institute for a clinical trial to assess a new imaging approach in prostate cancer monitoring. The study will test whether the addition of prostate-specific membrane antigen (PSMA) - positron emission tomography (PET) computed tomography (CT) (PSMA-PET CT) imaging modality to active surveillance regimens improves prostate cancer monitoring. With a possible two-year extension, this five-year grant will investigate if this imaging modality can minimise the requirement for biopsies during active surveillance of this cancer and eliminate its presence that needs treatment. According to Weill Cornell Medicine, PSMA-PET CT leverages a radioactive diagnostic agent for identifying a protein present on the surface of prostate cells and at higher levels on prostate cancer cells. This imaging technique is said to have already been employed to identify metastasis in high-risk cases and to monitor remission. Under this approach, patients are monitored through regular prostate-specific antigen (PSA) level blood tests, magnetic resonance imaging (MRI) scans, and biopsies to check for any signs of cancer progression. The study's principal investigator, Dr Timothy McClure, along with colleagues from Weill Cornell Medicine's department of radiology and the department of pathology's molecular imaging and therapeutics division, will assess whether PSMA-PET CT addition can enhance the specificity and sensitivity of prostate cancer surveillance while minimising screening-related harm. Dr McClure said: 'Our trial leverages cross-sector collaboration to innovate and streamline care for patients with prostate cancer. 'We hope to develop alternatives for prostate cancer surveillance that help us more effectively stratify which patients need treatment.' Weill Cornell Medicine noted that 200 men with low-risk or intermediate-risk prostate cancer will be assigned by the researchers, and the trial will enrol subjects at NewYork-Presbyterian/Weill Cornell Medical Center and four additional sites. The study is also supported by Lantheus, the producer of the diagnostic agent used in PSMA-PET CT. The research is partly supported by the National Cancer Institute. Last month, Weill Cornell Medicine researchers and the New York Genome Center identified a method for cancer detection via blood test, using whole-genome sequencing and error correction. "Weill Cornell receives grant to test new imaging approach for prostate cancer" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
09-05-2025
- Business
- Yahoo
Lantheus price target lowered to $120 from $134 at JonesResearch
JonesResearch lowered the firm's price target on Lantheus (LNTH) to $120 from $134 and keeps a Buy rating on the shares following the Q1 report. With Pylarify facing competitive pressure and its net sales down 0.5% year-over- year, an ongoing business reorganization and reduced fiscal 2025 earnings guidance, the stock has faced significant negative pressure, the analyst tells investors in a research note. The firm acknowledges near-term concerns over emerging PSMA-PET competition and potential increased operating expenses arising from recent acquisitions, but continues to have confidence in the medium- to long-term potential of Lantheus' radiopharmaceutical pipeline. It expects strong execution and improved margins following the completion of acquisitions and divestitures. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on LNTH: Disclaimer & DisclosureReport an Issue Lantheus: Strategic Growth Potential and Market Positioning Justify Buy Rating Despite Challenges Lantheus Holdings Reports Q1 2025 Financial Results Lantheus Holdings Earnings Call: Mixed Outlook Amid Strategic Moves Balancing Challenges and Opportunities: Justin Walsh's Optimistic Buy Rating for Lantheus Holdings Amidst Strategic Reorganization Strategic Growth and Focus: Lantheus's Positive Long-Term Outlook Justifies Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
